In a series of acromegalic patients the effects of CV 205-502, a new long-acting dopamine-agonist drug, on growth hormone (GH), insulin-like growth factor I (IGF-I) and prolactin (PRL) 
Recently, a non-ergot dopamine agonist, octahydrobenzo[g]quinoline , with a high affinity for D2-receptors and a weak affinity for Dt-receptors has been developed (1) .
A marked PRL-lowering activity of this drug, lasting more than 24 h, has already been shown both in healthy subjects and in hyperprolactinemic patients (2, 3) , even when resistant to bromocriptine treatment (4) . Dopamine agonist drugs, such as bromocriptine, lisuride and terguride, have been in use for 20 years in the medical treatment of acromegaly (5) . However, results are often disappointing because normalization of GH levels occurs in a minority of patients (6) and because the effect of these drugs in responsive patients is usually short-lived (7) , thus necessitating multiple administra¬ tions to control GH hypersécrétion throughout the day.
The long-iasting and potent dopaminergic effect of CV 205-502 (2) (Fig. la) . A significant inhibition (p<0.05) vs baseline, saline infusion and CV 205-502 administration was observed in GH levels (Fig. la) . The analysis of individual data showed that in 8 out of 12 patients (case nos 1-4, 6, 7, 10 and 12) the GH levels declined by more than 50% as compared to baseline.
The PRL suppression was similar to that observed after acute administration of CV 205-502 up to 6 h but was significantly minor 8 h after administration (Fig. lb) In one patient (case no. 9) given an acute treatment of These data thus confirm and support previous studies (3, 4) showing the long-lasting dopaminergic activity of this new drug. (9) .
